Merck Sharp & Dohme (MSD) announced the FDA approval of LIPFENDRA (eniclitide decanoate) on July 15, 2026, a pioneering oral drug designed to delay gastric emptying to improve glycemic control. This landmark decision signals a strategic opportunity for the company to capture new market share in the oral glucagon-like peptide-1 receptor agonist space.